These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 9881109)
21. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety. Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613 [TBL] [Abstract][Full Text] [Related]
23. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714 [TBL] [Abstract][Full Text] [Related]
24. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket. Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246 [TBL] [Abstract][Full Text] [Related]
25. Nonpeptidic HIV protease inhibitors: 4-hydroxy-pyran-2-one inhibitors with functional tethers to P1 phenyl ring to reach S3 pocket of the enzyme. Vara Prasad J; Tummino PJ; Ferguson D; Saunders J; Vander Roest S; McQuade TJ; Heldsinger A; Reyner EL; Stewart BH; Guttendorf RJ; Para KS; Lunney EA; Gracheck SJ; Domagala JM Biochem Biophys Res Commun; 1996 Apr; 221(3):815-20. PubMed ID: 8630044 [TBL] [Abstract][Full Text] [Related]
26. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835 [TBL] [Abstract][Full Text] [Related]
27. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups. Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129 [TBL] [Abstract][Full Text] [Related]
29. Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. Ghosh AK; Thompson WJ; Fitzgerald PM; Culberson JC; Axel MG; McKee SP; Huff JR; Anderson PS J Med Chem; 1994 Aug; 37(16):2506-8. PubMed ID: 8057296 [No Abstract] [Full Text] [Related]
30. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors. Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711 [TBL] [Abstract][Full Text] [Related]
31. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478 [TBL] [Abstract][Full Text] [Related]
32. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold. Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738 [TBL] [Abstract][Full Text] [Related]
33. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. Turner SR; Strohbach JW; Tommasi RA; Aristoff PA; Johnson PD; Skulnick HI; Dolak LA; Seest EP; Tomich PK; Bohanon MJ; Horng MM; Lynn JC; Chong KT; Hinshaw RR; Watenpaugh KD; Janakiraman MN; Thaisrivongs S J Med Chem; 1998 Aug; 41(18):3467-76. PubMed ID: 9719600 [TBL] [Abstract][Full Text] [Related]
35. Calculation of relative differences in the binding free energies of HIV1 protease inhibitors: a thermodynamic cycle perturbation approach. Reddy MR; Varney MD; Kalish V; Viswanadhan VN; Appelt K J Med Chem; 1994 Apr; 37(8):1145-52. PubMed ID: 8164256 [TBL] [Abstract][Full Text] [Related]
36. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor. Hill R Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407 [No Abstract] [Full Text] [Related]
40. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands. Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]